# NuclearMediX

Source: https://onco.cc/companies/nuclearmedix/  
OnCo record `nuclearmedix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NuclearMediX is an Imperial College London spin-out making a PET scan tracer that shows neuroendocrine tumours and can be produced on simple single-use cassettes. It is also working on radioactive treatments.

## Summary

NuclearMediX Limited was incorporated in England on 13 December 2024 to commercialise research from Professor Eric Aboagye's lab at Imperial College London; Aboagye and Dr Ruisi Fu (managing director) are co-founders. Its lead product, NMX-001A (FETO, [18F]FET-βAG-TOCA), is a fluorine-18 PET tracer targeting somatostatin receptor 2 (SSTR2), which the company lists as phase 2 completed, with an initial focus on neuroendocrine tumours. It is designed to be made on single-use, automation-ready cassettes for multi-site production, and the platform also lists astatine-211 (alpha) and terbium-161 (Auger electron) therapeutic programmes. The company reports completing Innovate UK's ICURe programme with a GBP 300,000 grant (2024 to 2026) and a UK production partnership near the Cambridge Biomedical Campus (March 2026).

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: London
- Type: radiopharma
- Website: https://www.nuclearmedix.com/

## Notes

- Incorporation date from Companies House (company 16134861). The phase 2 status of FETO is the company's statement; the underlying studies were academic work at Imperial and were not checked here. No equity financing is disclosed.

## Sources

- Official website: https://www.nuclearmedix.com/
- Companies House record: https://find-and-update.company-information.service.gov.uk/company/16134861
- News: https://www.nuclearmedix.com/news

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Astatine-211 alpha therapy](https://onco.cc/technologies/astatine-211-alpha-therapy/), [PET tracer manufacturing and distribution](https://onco.cc/technologies/pet-tracer-manufacturing/), [Somatostatin receptor PET (68Ga/64Cu-DOTATATE)](https://onco.cc/technologies/sstr-pet/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)

---
JSON: https://onco.cc/api/v1/entities/nuclearmedix.json